Compare ACCS & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCS | XLO |
|---|---|---|
| Founded | 1988 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.0M | 39.4M |
| IPO Year | N/A | 2021 |
| Metric | ACCS | XLO |
|---|---|---|
| Price | $7.47 | $0.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $14.00 | $2.00 |
| AVG Volume (30 Days) | 15.1K | ★ 437.3K |
| Earning Date | 01-01-0001 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,344,000.00 |
| Revenue This Year | $0.18 | $626.78 |
| Revenue Next Year | $7.16 | $79.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.75 | $0.50 |
| 52 Week High | $13.35 | $1.18 |
| Indicator | ACCS | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 39.47 |
| Support Level | $6.75 | $0.50 |
| Resistance Level | $8.77 | $0.74 |
| Average True Range (ATR) | 0.33 | 0.04 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 64.29 | 23.44 |
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.